40859
document
Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome . OBJECTIVE To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism , insulin resistance , cervical scores , and pregnancy rates in women with clomiphene citrate ( CC ) -resistant polycystic ovary syndrome ( PCOS ) . METHODS Thirty-seven women with CC-resistant PCOS were randomly assigned to be pretreated with 500 mg of metformin or placebo 3 times per day for 2 cycles , and 100 mg of CC was given on days 5 through 9 of the second cycle in both groups . Luteinizing hormone ( LH ) , follicle stimulating hormone ( FSH ) , dehydroepiandrostendione sulfate ( DHEAS ) , total testosterone ( T ) , glucose , and insulin levels were measured at baseline and after the first cycle , as well as body mass index ( BMI ) , cervical score , and pregnancy rate . RESULTS After 1 cycle , BMI , total T level , and percentage of participants with insulin resistance were significantly decreased in the metformin group , without any significant decrease in LH , FSH , and DHEAS levels ; and in the second cycle , CC treatment resulted in a higher ovulation rate and a thicker endometrium in the metformin group . The pregnancy rate and cervical scores were also higher in that group . CONCLUSION The short-course pretreatment with metformin decreased hyperandrogenism and insulin resistance and improved cervical sores , ovulation rate , and pregnancy rate among women with CC-resistant PCOS .
40860
Intervention_Pharmacological
metformin
40861
Intervention_Pharmacological
metformin
40862
Intervention_Pharmacological
clomiphene citrate
40863
Intervention_Pharmacological
metformin
40864
Intervention_Pharmacological
placebo
40865
Intervention_Pharmacological
CC
40866
Intervention_Pharmacological
metformin
40867
Intervention_Pharmacological
CC
40868
Intervention_Pharmacological
metformin
40869
Intervention_Pharmacological
metformin
40870
Outcome_Physical
hyperandrogenism
40871
Outcome_Physical
insulin resistance
40872
Outcome_Physical
cervical scores
40873
Outcome_Physical
pregnancy rates
40874
Outcome_Physical
Luteinizing hormone ( LH )
40875
Outcome_Physical
follicle stimulating hormone ( FSH )
40876
Outcome_Physical
dehydroepiandrostendione sulfate ( DHEAS )
40877
Outcome_Physical
total testosterone ( T )
40878
Outcome_Physical
glucose
40879
Outcome_Physical
insulin levels
40880
Outcome_Physical
body mass index ( BMI
40881
Outcome_Physical
cervical score
40882
Outcome_Physical
pregnancy rate
40883
Outcome_Physical
BMI
40884
Outcome_Physical
total T level
40885
Outcome_Physical
percentage of participants with insulin resistance
40886
Outcome_Physical
LH
40887
Outcome_Physical
FSH
40888
Outcome_Physical
DHEAS levels
40889
Outcome_Physical
ovulation rate
40890
Outcome_Physical
thicker endometrium
40891
Outcome_Physical
pregnancy rate
40892
Outcome_Physical
cervical scores
40893
Outcome_Physical
hyperandrogenism
40894
Outcome_Physical
insulin resistance
40895
Outcome_Physical
cervical sores
40896
Outcome_Physical
ovulation rate
40897
Outcome_Physical
pregnancy rate
40898
Participant_Condition
clomiphene citrate-resistant
40899
Participant_Sex
women
40900
Participant_Condition
polycystic ovary syndrome .
40901
Participant_Sex
women
40902
Participant_Condition
clomiphene citrate ( CC ) -resistant polycystic ovary syndrome ( PCOS )
40903
Participant_Sample-size
Thirty-seven
40904
Participant_Condition
CC-resistant PCOS were randomly assigned
40905
Participant_Sex
women
40906
Participant_Condition
CC-resistant PCOS